Polypharmacy or medication washout: An old tool revisited

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 639-648

  Hoffman, Daniel A ^a   Schiller, Mark ^b   Greenblatt, James M ^c   Iosifescu, Dan V ^d  

^a Neuro Therapy Clinic PC   (United States)

^b Mind Therapy Clinic   (United States)

^c Comprehensive Psychiatric Resources ^*  (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Medication washout; Polypharmacy; Risk of polypharmacy

Indexed keywords

AMFEBUTAMONE PLUS ESCITALOPRAM; ESCITALOPRAM; MIRTAZAPINE PLUS VENLAFAXINE; NEUROLEPTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; COMBINATION CHEMOTHERAPY; CONDUCT DISORDER; DELIRIUM; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; HEALTH STATUS; HUMAN; INFORMED CONSENT; INSOMNIA; MEDICATION WASHOUT; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NERVOUSNESS; PATIENT EDUCATION; POLYPHARMACY; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PSYCHOSIS; SCHIZOPHRENIA; SENSORY DYSFUNCTION; SHOCK; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; XEROSTOMIA;

EID: 80955155004     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s24375     Document Type: Article

References (56)

1. NASMHPD Medical Directors' Technical Report on Psychiatric Polypharmacy. Sep 2001. National Association of State Mental Health Program Directors Medical Directors Council and State Medicaid Directors. Available from: http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Polypharmacy. Accessed Septemeber 18, 2011.
2. Kingsbury SJ, Yi D, Simpson GM. Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv. 2001;52(8):1033-1036.
3. Texas Department of Aging and Disability Services. Polypharmacy definition developed by DADS Pharmacy Services, May 2009. Available from: http://www.dads.state.tx.us/qualitymatters/qcp/polypharmacy. Accessed August 14, 2011.
4. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15-31.
5. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.
6. Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70(2):155-162.
7. DePaulo JR. Bipolar disorder treatment: an evidence-based reality check. Am J Psychiatry. 2006;163(2):175-176.
8. Watanabe N, Omori IM, Nakagawa A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010;24(1):35-53.
9. Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;15(2):CD006117.
10. Nakagawa A, Watanabe N, Omori IM, et al. Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis. CNS Drugs. 2008;22(7):587-602.
11. Cipriani A, Geddes JR, Furukawa TA, Barbui C. Metareview on shortterm effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry. 2007;52(9):553-562.
12. Insel TR. Disruptive insights in psychiatry: transforming a clinical discipline. J Clin Invest. 2008;119(4):700-705.
13. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71(4): 463-474.
14. Greenberg G. Inside the battle to define mental illness. Wired. Jan 2011.
15. Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. J Clin Psychiatry. 2008;69(7): 1064-1074.
16. Gaynes B, Rush A, Trivedi M, et al. The STAR*D study: Treating depression in the real world. Cleve Clin J Med. 2008;75(1):57-66.
17. Fava GA, Tomba E, Grandi S. The road to recovery from depression - don't drive today with yesterday's map. Psychother Psychosom. 2007; 76(5):260-265.
18. Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord. 2008;10(3):957-968.
19. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom. 2010;79(5):267-279.
20. Pigott HE. STAR*D: A tale and trail of bias. Ethical Hum Psychol Psychiatry. 2011;13(1):6-28.
21. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61(1):9-15.
22. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67(1):26-36.
23. Gunderson JG. Clinical practice. Borderline personality disorder. N Engl J Med. 2011;364(21):2037-2042.
24. Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011; 168(7):689-701.
25. Yury CA, Fisher JE, Antonuccio DO, Valenstein M, Matuszak J. Meta- analysis of antidepressant augmentation: piling on in the absence of evidence. Ethical Hum Psychol Psychiatry. 2009;11(3):171-182.
26. Van Brunt DL, Gibson PJ, Ramsey JL, Obenchain R. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States.1997-2000. Med Gen Med. 2003;5(3):16.
27. Mark, Tami L. For what diagnoses are psychotropic medications being prescribed? A nationally representative survey of physicians. CNS Drugs. 2010;24(4):319-326.
28. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306(5): 493-502.
29. ClinicalTrials.gov. A review of clinical trials on the website. Available from http://www.clinicaltrials.gov/ct2/results?term=atypical+antipsychotics/. Accessed October 10, 2011. Accessed March 11, 2011.
30. Nardo JM. The gird. One Boring Old Man Blog. Available from: http://1boringoldman.com/index.php/2011/01/04/the-grid/. Accessed February 18, 2011.
31. Nelson CJ, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
32. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-351.
33. Gurvich T, Cunningham JA. Appropriate use of psychotropic drugs in nursing homes. Am Fam Physician. 2000;61(5):1437-1446.
34. Feil D, Weinreb J, Sultzer D. Psychiatric disorders and psychotropic medication use in elderly persons with diabetes. Ann Longterm Care. 2006;14(7):39-47.
35. Nicole Damestoy N, Collin J, Lalande R. Prescribing psychotropic medication for elderly patients: some physicians' perspectives. CMAJ. 1999;161(2):143-145.
36. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug misuse in the elderly. Clin Geriatr Med. 1992;8(1):143-158.
37. Goren JL, Parks JJ, Ghinassi FA, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf. 2008;34(10):571-582.
38. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple vs single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700-706.
39. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-127.
40. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325-329.
41. Kingsbury L. Psychiatric polypharmacy: the good, the bad, and the ugly. Psychiatr Times. 2007;24(4):1-3.
42. John Wanamaker. US department store merchant1838-1922. Available from: http://en.wikipedia.org/wiki/John_Wanamaker. Accessed April 14, 2011.
43. Helwick C. Polypharmacy is common in psychiatry, but is more better? Medscape Medical News. Available from: http://www.medscape.com/viewarticle/728132. Accessed
44. Dao J, Carey B, Frosh D. For some troops, powerful drug cocktails have deadly results. New York Times. February 12, 2011. Available from: http://www.nytimes.com/2011/02/13/us/13drugs.html?ref=benedictcarey. Accessed September 16, 2011.
45. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97-105.
46. Hoffman DA, DeBattista C, Schiller M. Medication washout: imposing discontinuation or a diagnostic and therapeutic tool? Poster 230 presented at the US Psychiatric and Mental Health Congress, San Diego, CA, October 30-November 2, 2008.
47. DeBattista C, Kinrys G, Hoffman D, et al. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011;45(1):64-75.
48. Grunebaum MF, Oquendo MA, Burke AK, et al. Clinical impact of a 2 week psychotropic medication washout in unipolar depression inpatients. J Affect Disord. 2003;75(3):291-296.
49. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
50. Hoffman DA. First, do no harm - a basic tenet in jeopardy? J Neurother. 2007;10(4):53-61.
51. Patel JK, Green AI, Kalinowski A, Tsuang MT. Evaluation of a complex case: the value of a drug washout period. Am J Psychiatry. 1997; 154(12):1747-1750.
52. Viguera AC, Baldessarini RJ, Hegerty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49-55.
53. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care, J Clin Psychiatry. 2006; 67(3):453-460.
54. Novick D, Haro JM, Suarze D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109-113.
55. Dutta R, Murray RM, Allardyce J, Jones PB, Boydell J. Early risk factors for suicide in an epidemiological first episode psychosis cohort. Schizophr Res. 2011;126(1-3):11-19.
56. Friedman R, Malone P. Rules of the Road: A Plaintiff Lawyer's Guide to Proving Liability. 2nd ed. Portland, OR: Trial Guides LLC; 2010.